Investment Rating - The industry investment rating is "Positive" [10] Core Insights - The report highlights strong performance in the beauty and personal care sector, particularly in the medical aesthetics and cosmetics segments, with notable revenue growth and profitability in key companies [9][41] - The report emphasizes the importance of emotional consumption and the demand for innovative products that meet consumer needs, particularly in the context of domestic brands gaining market share [44][45] Summary by Sections Market Review - The beauty care index rose by 2.75% in February, outperforming the broader market [15] - In the medical aesthetics sector, companies like Huahan Co. and Pumen Technology saw significant stock price increases, while in cosmetics, Qing Song Co. and Beitaini led the gains [6][25] Medical Aesthetics Performance - Jinbo Bio reported a revenue of 1.595 billion yuan for 2025, a year-on-year increase of 10.57%, but a net profit decline of 11.08% due to increased costs and strategic adjustments [7][31] - Huaxi Bio's revenue for 2025 was 4.217 billion yuan, down 21.49%, while net profit surged by 67.03% due to cost management and strategic realignment [34][34] Cosmetics Performance - The 38 promotional event showcased strong performance for domestic brands, with significant sales figures reported from live streaming channels [8][36] - Upme Co. projected a revenue of 9.1-9.2 billion yuan for 2025, reflecting a growth of 34.0%-35.4%, driven by its successful brand strategy [41][41] Investment Recommendations - The report recommends focusing on high-quality companies in the medical aesthetics and cosmetics sectors that cater to emotional consumption trends, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][44] - In cosmetics, brands that innovate with emotional value and safe ingredients are favored, with recommendations for companies like Porlaia and Upme Co. [45][46]

Investment Rating - The industry investment rating is "Overweight" [48] Core Insights - The report highlights strong performance in the domestic beauty and medical aesthetics sectors, with notable revenue growth and profit improvements for key companies [4][41] - The report emphasizes the importance of emotional consumption and the demand for innovative products in the beauty industry, particularly among domestic brands [44][45] Summary by Sections Market Review - In February, the beauty care index rose by 2.75%, outperforming the broader market [13] - Notable stock performances included Huahan Co. (+3.4%) and Pumen Technology (+2.5%) in the medical aesthetics sector, while Qingsong Co. (+16.6%) and Beitaini (+12.5%) led in the cosmetics sector [3][18][23] Medical Aesthetics - Jinbo Bio reported a 2025 revenue of 1.595 billion yuan, a 10.57% increase year-on-year, but a net profit decline of 11.08% due to increased R&D and marketing costs [4][29] - Huaxi Bio's revenue fell by 21.49% to 4.217 billion yuan, while net profit surged by 67.03% due to cost management and non-recurring gains [4][32] Cosmetics - The 38 promotional event saw strong sales for domestic brands, with significant performance from brands like Porlaia and Beitaini [5][36] - Upcoming earnings for Shumei Co. are projected to show a revenue increase of 34.0%-35.4% and a net profit growth of 41.9%-44.4% [41] Investment Recommendations - The report recommends focusing on high-quality companies in the medical aesthetics sector that are expanding their market presence, such as Meilitiantian Medical Health and Aimeike [6][44] - In cosmetics, it suggests investing in brands that emphasize emotional value and innovative ingredients, highlighting companies like Porlaia and Shumei Co. [45][47]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of domestic brands during the 38 promotional event, with significant sales figures and consumer demand for effective skincare products [23][25] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [6][30][31] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 3.91% and 3.63% respectively during the week of March 2 to March 6, 2026 [5][15] - Year-to-date, the retail index has decreased by 6.82%, while the social services index has increased by 3.01% [15][16] Industry Dynamics - Domestic brands performed well during the 38 promotional event, with leading brands like Proya achieving significant sales [23] - The report notes that the skincare product category is seeing strong demand, particularly for effective and functional products [23][25] Investment Recommendations - Investment focus areas include: - **Gold and Jewelry**: Recommend brands with differentiated product offerings such as Laopuhuang and Chaohongji [6][30] - **Offline Retail**: Highlight companies adapting to trends like Yonghui Supermarket and Aiyingshi [6][30] - **Cosmetics**: Focus on brands that meet emotional value and safety innovation, recommending brands like Maogeping and Proya [6][31] - **Medical Aesthetics**: Suggest companies with differentiated products and expanding chains, such as Meilitiantian Medical Health and Aimeike [6][31] Company Performance Highlights - **Shangmei Co.**: Expected revenue of 9.1-9.2 billion yuan for 2025, with a year-on-year growth of 34.0%-35.4% [27] - **Zhou Dafu**: Achieved a retail value increase of 17.8% year-on-year in Q3 2026 [32] - **Yonghui Supermarket**: Anticipated revenue decline but undergoing significant operational adjustments [32]

Core Insights - Filorga, a well-known French skincare brand, announced its withdrawal from the Chinese market, closing its Tmall flagship store on January 31, 2026, along with its 3.03 million followers and popular products like the "Ten Full Nourishing Mask" [1] - The exit of Filorga is part of a broader trend, with over 60 foreign beauty brands leaving the Chinese market between 2024 and 2025, indicating a significant retreat of foreign skincare brands [1] - Domestic beauty brands have gained market share, surpassing foreign brands for the first time in 2023, with Proya becoming the first domestic brand to exceed 10 billion yuan in revenue [1] Group 1: Filorga's Market Performance - Filorga entered the Chinese market in 2015 and quickly gained popularity, achieving a sales record of over 1 billion yuan during the 2018 Double Eleven shopping festival, with a year-on-year growth of 148% [2] - However, growth slowed significantly after 2020, attributed to ineffective pricing strategies and a lack of competitive advantage against domestic brands [2][3] - The brand's high-priced star product, the mask priced at 599 yuan, failed to maintain its premium image due to frequent discounts, while domestic competitors offered more affordable alternatives [2] Group 2: Challenges in Channel Operations - Filorga's online sales performance was poor, with only 2.5 million to 5 million yuan in sales on Douyin in 2025, indicating a lack of effective online marketing strategies [3] - The closure of physical stores resulted in a loss of high-end brand image and direct consumer engagement opportunities [3] - In contrast, other brands under the L'Oréal group, such as La Roche-Posay and Kiehl's, maintained strong market positions through effective product offerings and operational strategies [3] Group 3: Broader Industry Trends - The withdrawal of Filorga aligns with Colgate's global strategy to streamline operations, as the company's personal care segment saw a 2.05% decline in net sales in the first half of 2025 [4] - Similar strategic adjustments are occurring across the foreign beauty sector, with brands like Shiseido and LVMH also closing stores or withdrawing from the market due to declining performance [5] - Domestic brands like Proya and Winona have shown significant growth, with Proya achieving over 10.778 billion yuan in revenue in 2024, marking a year-on-year increase of over 20% [5] Group 4: Future Outlook - Analysts suggest that the challenges faced by foreign brands are not solely due to their foreign status but rather their inability to adapt to the Chinese market and consumer preferences [6] - L'Oréal's success is attributed to its localized operations, contrasting with Filorga's failure to establish a coherent market strategy in China [6] - The Chinese high-end beauty market is expected to continue facing challenges, but opportunities remain for brands that can effectively engage with local consumers [6]

Core Insights - The article discusses the rising demand for sensitive skin care products in China, driven by a significant portion of the population experiencing skin sensitivity issues, with estimates suggesting that 30% of individuals are affected [3][4][6]. - The sensitive skin care market in China is projected to reach a scale of 66.44 billion yuan by June 2025, indicating a robust growth trajectory [4]. - Domestic brands, particularly those focusing on sensitive skin, have gained substantial market share, with brands like Winona and Huaxi Biological showing remarkable growth in sales and market presence [6][11][17]. Market Dynamics - The sensitive skin care market is characterized by a high incidence of skin sensitivity, with a daily occurrence rate of 64.1% among consumers [3]. - The demand for sensitive skin care products has led to the emergence of a billion-dollar market, with brands capitalizing on the need for effective solutions [4][6]. - The competitive landscape is shifting, with domestic brands outperforming international counterparts in terms of market share, reaching nearly 49.1% by 2022 [17]. Consumer Behavior - Consumers are increasingly willing to invest in skin care products to address their skin issues, often resorting to multiple purchases and trying various products to find effective solutions [6][25]. - The article highlights the psychological impact of skin conditions on consumers, leading to a cycle of purchasing and dissatisfaction as they seek effective remedies [9][28]. - The trend of "medical beauty" is on the rise, with a growing number of individuals seeking cosmetic procedures to enhance their appearance, further fueling the demand for sensitive skin care products [8][9]. Brand Strategies - Domestic brands have shifted their strategies from affordability to premium pricing, with significant price increases observed in their product lines [20][21]. - The article notes that brands are increasingly focusing on innovation and technology to differentiate themselves in a crowded market, with a notable increase in patent applications related to sensitive skin care [32]. - Marketing strategies have evolved, with brands now emphasizing product efficacy and scientific backing rather than solely relying on influencer endorsements [32][33].

以下文章来源于财经天下WEEKLY ，作者财经天下 财经天下WEEKLY . 《财经天下》周刊官方账号，提供有品质的深度报道，讲述中国企业在时代浪潮中的精彩故事。 毛利率在80%以上，研发投入却较低。 作者：林木 编辑：吴跃 来源：财经天下WEEKLY 因为陷入"EGF（表皮生长因子）罗生门"，可复美近期被推上风口浪尖。 不久前，有消费者反映可复美产品"违规添加EGF"。随后可复美母公司巨子生物予以否认， 称"旗下所有产品均未添加"。伴随着舆论发酵，社媒平台上，看客们吵得沸沸扬扬，力挺声、 质疑声四起，也让"可复美"这个名字被更多人知晓。 做过医美或者皮肤敏感的消费者，大多对"可复美"三个字不陌生。这个主打皮肤修复的品牌， 早年间主要深耕院线渠道，之后乘上直播电商风口，进入更多人视野，撬开更多钱包。过去6 年，其母公司巨子生物营收从9.57亿元涨至55.39亿元，翻了5倍多。 2024年，巨子生物一举超越珀莱雅，成为市值最高的国货美妆公司，此后一直保持至今。公 司创始人，现年59岁的陕西人范代娣，也因此登顶国货美妆首富。 爱美的女生，这些年托举过不少美妆公司。当下风头最盛的可复美和巨子生物，到底是何来 头？为 ...